Contact Us
Drug Search Results
More Filters [+]

Aciclovir

Alternative Names: aciclovir, acyclovir, zovirax, acyclovir sodium, acyclovir lauriad, me-609, me609, me 609, sitavig, avaclyr, acyclovix, xerese
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Aciclovir is a synthetic compound with a similar molecular structure to purine nucleoside. It has been shown to stop the growth of herpes simplex virus (HSV), Varicella zoster virus (VZV) (the cause of chickenpox and shingles), Epstein-Barr virus (EBV, the cause of infectious mononucleosis), and to a lesser extent cytomegalovirus (CMV).

Mechanisms of Action: DNA Polymerase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Keratitis | Herpes Simplex | Keratitis, Dendritic | Keratitis, Herpetic | Herpes Labialis

Known Adverse Events: Eye Pain | Pain Unspecified | Conjunctivitis | Keratitis | Headache

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aciclovir

Countries in Clinic: Poland, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Herpes Labialis|Herpes Simplex

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
OP-LIPC02

P3

Unknown Status

Herpes Labialis

2025-10-25

NCT05098938

P3

Completed

Herpes Simplex|Herpes Labialis

2023-07-19

Recent News Events

Date

Type

Title

11/15/2024

News Article

 NINER Pharmaceutical Strengthens Global Presence with Strategic IV Fluid Supply Initiative for the U.S. and Latin American Markets

09/03/2024

News Article

 Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

08/28/2024

News Article

 Lyranda, a Breakthrough Cold Sore Treatment, is Now Available in the U.S.

07/30/2024

News Article

 AiCuris Appoints Cynthia Wat as Chief Medical Officer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions